Conversely, PYCR2, while less studied, shows promise as a prognostic biomarker in hepatocellular carcinoma and colorectal cancer [11,25], with PYCR3 having limited exploration primarily in nasopharyngeal cancer [26]. This evidence concerns the gene PYCR2 and colorectal cancer.